Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients

Children's Hospital of Fudan University

Overview

prospectively compared Exclusive Enteral Nutrition with Infliximab in the clinical outcomes, mucosal healing, nutrition improvements, adverse effects and gastrointestinal microbiota changes on Chinese Children With active Crohn's Disease

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Crohn's Disease Exclusive Enteral Nutrition Infliximab Mucosal Healing

Interventions

InfliximabBIOLOGICAL

Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD

Exclusive Enteral NutritionDIETARY_SUPPLEMENT

the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).

Eligibility

Sex: ALLMin age: 1 YearMax age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: patients: 1. Pediatric active Crohn's disease ( CD) patients who were newly diagnosed at the Children's Hospital of Fudan University from October 2020 to Sep 2022，CD was diagnosed according to the Porto criteria and based on a combination of history, physical and laboratory examination, endoscopy with histology, and imaging of the small bowel (capsule endoscopy or magnetic resonance imaging or enhanced computerized tomography). 2. SES-CD\>4 and PCDAI \>10 at initial 3. For the patients whose fecal will be analyzed shouldn't take antibiotics or probiotics within the 1.5 months prior to the study and during the treatment. healthy controls: 1. free medical history 2. had not taken antibiotics or probiotics within the 1.5 months prior to donate their fecal Exclusion Criteria: 1. patients who had gene mutation or combined with other intestinal diseases such as tuberculosis or EB infection 2. for patients in the EEN group who could not finish the daily prescribed volume of formula for any reason; for the patients in the IFX group who could not finish the first 4 times IFX injection for any reason. 3. patients who were administered EEN, corticosteroids, immunosuppressive drugs, or biological agents prior to the study; 4. patients who could not attend consecutive follow-up sessions;

Outcomes

Primary Outcomes

the number of patients who reach mucosal healing at the end of treatment in Exclusive enteral nutrition group

the mucosal healing was defined as Simple Endoscopic Score for CD （SES-CD ）≤4 at the end of treatment . For the SES-CD, the intestine is divided into 5 anatomic segments under the endoscopic vision: rectum, left side of the colon segment, transverse colon, right side of the colon segment, and ileum. Items of interest include ulcer size, estimates of the ulcerated and affected surface, and the presence of luminal narrowing. The SES-CD score is calculated by combining scores of individual segments. Overall SES-CD scores are classified into 4 disease categories: none, 0 to 2; mild 2 to 4; moderate 5 to 15; and severe\>16.

Time frame: at the end of 8 week of treatment.

the number of patients who reach mucosal healing at the end of treatment in Infliximab group

Time frame: at the end of 14 week of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.